Dibash Kumar Das - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Dibash Kumar Das's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Dibash Kumar Das
Verified
Associate Director, Clinical Content Hub, Haymarket Media
New York
Beats
Healthcare
Anything that is not family-friendly.
Content
By Dibash Kumar Das| focusononcology.com@ By Dibash Kumar Das, PhDThe NATALEE trial has revealed promising results for younger women with hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). Research shows that ribociclib (RIB), when paired with a nonsteroidal aromatase inhibitor (NSAI), significantly improves invasive disease-free survival (iDFS). This breakthrough is particularly notable for women under 40, a group historically associated with more aggressive disease and poorer outcomes.
By Dibash Kumar Das| focusononcology.com@ By Dibash Kumar Das, PhDThe CAPItello-290 Phase III trial, long-awaited by the oncology community, delivered mixed results for the combination of capivasertib and paclitaxel as a first-line treatment for metastatic triple-negative breast cancer (mTNBC).
By Dibash Kumar Das| focusononcology.com@ By Dibash Kumar Das, PhDThe CAPItello-290 Phase III trial, long-awaited by the oncology community, delivered mixed results for the combination of capivasertib and paclitaxel as a first-line treatment for metastatic triple-negative breast cancer (mTNBC).
Company Info
Haymarket Media
McMahons Point, New South Wales, Australia
+61 2 8399 7636